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Abstract: We have recently designed and synthesized a novel iminoquinone anticancer 
agent, 7-(4-fluorobenzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one 
(FBA-TPQ) and initiated its preclinical development. Herein we investigated its efficacy, 
safety, and pharmacokinetics in in vitro and in vivo models of human pancreatic cancer. 
Our results demonstrated that FBA-TPQ inhibited pancreatic cancer cell growth, induced 
apoptosis, and caused cell cycle arrest in vitro. It inhibited the growth of xenograft tumors 
with minimal host toxicity. To facilitate future preclinical and clinical development of the 
agent, we also developed and validated a Rapid Resolution Liquid Chromatography (RRLC) 
method for quantitative analysis of FBA-TPQ in plasma and tissue samples. The method 
OPEN ACCESSMar. Drugs 2012, 10  1139 
 
 
was found to be precise, accurate, and specific. Using this method, we carried out in vitro 
and in vivo evaluations of the pharmacological properties of FBA-TPQ, including stability 
in plasma, plasma protein binding, metabolism by S9 enzymes, plasma pharmacokinetics, 
and tissue distribution. Our results indicate that FBA-TPQ is a potential therapeutic agent 
for pancreatic cancer, providing a basis for future preclinical and clinical development. 
Keywords: pancreatic cancer; marine anticancer agents; RRLC; pharmacokinetics 
 
1. Introduction 
Cancer remains a major public health problem despite the introduction of novel diagnostic 
procedures, improved surgical techniques and new radiation therapy technologies, alongside the 
development of targeted therapies. While the prognosis of many cancers is much better than a few 
decades ago, many cancers are still difficult to treat, especially pancreatic cancer, one of the most 
deadly of all cancers [1]. Standard therapy for pancreatic cancer is multimodal, involving surgery and 
chemotherapy. Since clinical symptoms are often non-specific and consequently most patients are 
diagnosed at advanced stages without any surgical options, chemotherapy becomes a limited choice of 
treatment. Thus far, gemcitabine has remained the single first-line chemotherapeutic agent for 
advanced pancreatic cancer; however, less than 25% of patients benefit from this drug [2]. Therefore, 
there is an urgent need to develop more effective and safer chemotherapeutic agents for pancreatic 
cancer. While the recently developed targeted therapies, such as trastuzumab, erlotinib, and imatinib, 
have improved the treatment outcomes of certain patients with cancer, new broad-spectrum 
chemotherapeutic agents with lower toxicity than the existing agents are still needed to achieve 
complete tumor eradication, to prevent recurrence, or to better prepare patients for curative resection. 
Additionally, such broad-spectrum agents may be useful in combination with targeted therapies to 
ensure the eradication of all cells, decreasing the likelihood of the development of acquired resistance.  
The search for new lead compounds is a crucial element in anticancer drug discovery. Natural 
products have historically provided many successful new anti-cancer drugs (e.g., doxorubicin, 
etoposide, paclitaxel, and gemcitabine). One class of the rich resources is marine products that have 
provided a large number of anticancer agents with novel structures [3–9]. To our best knowledge, 
cytarabine is the only US Food and Drug Administration (FDA)-approved marine-derived anticancer 
drug in the US Pharmacopeia. Trabectedin has been approved by the European Agency for the 
Evaluation of Medicinal Products (EMEA), and is under Phase III studies in the US. Examples of new 
experimental anticancer agents derived from marine natural products that have entered pre-clinical and 
clinical trials within the last decade include eribulin mesylate, soblidotin, plitidepsin, elisidepsin, 
PM1004, tasidotin and hemiasterlin [10].  
Makaluvamines, a class of marine iminoquinone alkaloids isolated from sponges of the genera 
Zyzzya, have been reported to have potent in vitro and in vivo cytotoxicity against several human 
cancer cell lines [10–12]. We have recently designed and synthesized several makaluvamine analogs 
and demonstrated their anti-cancer activities and safety in in vitro and in vivo tumor models [11–15]. 
7-(4-fluorobenzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one (FBA-TPQ; Figure 1a), Mar. Drugs 2012, 10  1140 
 
 
one of the most effective compounds in the class has been shown to increase apoptosis, inhibit 
proliferation and decrease cell viability of prostate [13], breast [14] and ovarian cancer cells [15],  
and to decrease the growth of breast and ovarian cancer xenograft tumors, with an acceptable safety 
profile [14,15]. In the present report, we evaluated the anti-tumor activities of FBA-TPQ against 
pancreatic cancer cells. As part of the continuing development of this compound, we developed a rapid 
resolution liquid chromatography (RRLC) method for FBA-TPQ. We validated the new RRLC method 
for various biological matrices, and examined the in vitro and in vivo pharmacological properties of 
FBA-TPQ, following intravenous and intraperitoneal administrations to BALB/c mice. We believe that 
the results presented here would provide a basis for future preclinical and clinical development of  
this compound.  
Figure 1. The structures of FBA-TPQ (a) and BA-TPQ (b) internal standard. 
 
2. Results and Discussion 
2.1. FBA-TPQ Exerts in Vitro Anticancer Activity against Pancreatic Cancer Cells 
2.1.1. Inhibition of Cancer Cell Growth 
We evaluated the effects of FBA-TPQ on the survival of several human pancreatic cancer cell lines, 
including HPAC (p53
+/+), Panc-1(p53
+/−), and Mia PaCa-2(p53
+/−), as well as normal IRM90 fetal 
fibroblast cells (Figure 2a). Cells were exposed to various concentrations of the test compound   
(0–10 µM) for 72 h, and cell survival rates were determined by the MTT assay, using a procedure 
reported previously [14,16,17]. FBA-TPQ exerted potent effects against the test cancer cell lines, 
leading to significant decreases in cell viability. As shown in Figure 2a, the compound demonstrated 
IC50 (the concentration that inhibits the survival of cells by 50%) values of less than 1 μM (0.11–0.54 μM); 
normal IMR90 fibroblasts were significantly less sensitive to the inhibitory effects of FBA-TPQ than 
the pancreatic cancer cells, with 10–50-fold differences in IC50, indicating the specificity of the compound.  
2.1.2. Induction of Apoptosis  
The apoptotic cells were detected using a method reported previously [14,18,19]. As illustrated in 
Figure 2b, FBA-TPQ induced apoptosis in a dose-dependent manner in all three cell lines. In HPAC 
cells, a 1 µM concentration of FBA-TPQ increased the apoptotic index two-fold higher than that seen 
in control cells (P < 0.01). In Panc-1 cells, FBA-TPQ at 1 µM demonstrated a four-fold increase in 
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apoptosis (P < 0.01). In the Mia PaCa-2 cells, FBA-TPQ at 1 µM led to a three-fold increase in 
apoptosis (P < 0.01). Although both of HPAC and Panc-1 cells showed a significant increase in 
apoptosis beginning at the 0.5 µM concentration (P < 0.01), the Panc-1 cells were significantly more 
sensitive than the HPAC cells (Figure 2b).  
Figure 2. (a) Cell growth inhibitory activity of FBA-TPQ in human pancreatic cancer cells 
and primary fibroblasts. HPAC, Panc-1, Mia PaCa-2 and IMR-90 cells were exposed to 
various concentrations of FBA-TPQ for 72 h, followed by MTT assay; (b) Induction of 
apoptosis in pancreatic cancer cells by FBA-TPQ. HPAC, Panc-1, Mia PaCa-2 cells were 
exposed to various concentrations of the compound for 48 h, followed by measurement of 
apoptosis by Annexin V assay/flow cytometry. The apoptotic index was calculated against 
untreated control cells; (c) Cell cycle progression effect of FBA-TPQ on human pancreatic 
cancer cells. Cells were exposed to various concentrations of the compound for 48 h, 
followed by determination of cell cycle distribution. All assays were performed in 
triplicate. (
# P < 0.05, * P < 0.01). 
 
2.1.3. Cell Cycle Arrest  
The effects of FBA-TPQ on cell cycle distribution were analyzed using the previously reported 
methods [20,21]; its effects appeared to be cell-line-dependent (Figure 2c). At 1 µM, FBA-TPQ 
induced an arrest in the G2/M phase (P < 0.01) in HPAC cells; in Panc-1 and Mia PaCa-2 cells, it 
induced arrest in the S phase (P < 0.01). The differences in the responses of the different cell lines may 
be related to their expression of p53. 
2.2. FBA-TPQ Decreases the Growth of Xenograft Tumors 
Since it exerted potent effects in vitro, we determined whether FBA-TPQ could also show anti-tumor 
effects in vivo. Nude mice bearing Panc-1 xenograft tumors were treated with vehicle or FBA-TPQ at 
5 or 10 mg/kg/day, 5 days per week. Compared with control group, treatments of 5 and 10 mg/kg/day Mar. Drugs 2012, 10  1142 
 
 
resulted in 77.8 (P < 0.01) and 90.1% (P < 0.01) inhibition of tumor growth, respectively (Figure 3a,b), 
with significant tumor regression or complete remission being seen in both treated groups. No 
significant host toxicity (using body weight as a surrogate marker) was observed at any of the doses 
(Figure 3c), suggesting that the FBA-TPQ can be safely given as a novel therapeutic agent. 
Figure 3. In vivo effects of FBA-TPQ administered to nude mice bearing Panc-1 xenograft 
tumors. (a) FBA-TPQ was administered by intraperitoneal (ip) injection at doses of   
5 mg/kg/day, 5 days/week for 3 weeks and 10 mg/kg/day, 5 days/week for 2 weeks, tumors 
were measured every three days; (b) At the end of the experiment, representative tumors 
were removed and photographed; (c) Animals were also monitored for changes in body 
weight as a surrogate marker for toxicity. 
 
Previous studies have shown that FBA-TPQ has nanomolar/low micromolar IC50 values against 
prostate, breast, and ovarian cancer cell lines [13–15]. The compound inhibited cell growth, decreased 
cell proliferation, induced apoptosis, and arrested cell cycle distribution. In addition, normal cells were 
not as sensitive to the compound. In vivo study demonstrated that FBA-TPQ has potent activity against 
breast and ovarian cancer xenograft tumors [14,15]. Mechanistic studies revealed that FBA-TPQ 
down-regulated MDM2, E2F1, Bcl-2, PI3K proteins, up-regulated Fas, Bax, p53/p-p53, ATM/p-ATM, 
γH2AX, and led to increased cleavage of caspases-3, -8 and -9 both in vitro and in vivo [13–15]. These 
findings suggested that FBA-TPQ has potent anti-cancer activity due to inhibition of oncogenes, 
activation of the DNA damage response and PI3K-Akt pathways. In summary, our preclinical efficacy 
and safety data indicate that FBA-TPQ can be a candidate anticancer drug for future development.  
In subsequent studies, we developed analytical methods and determined pharmacological properties of 
the compound, including initial pharmacokinetic and metabolic studies.  
2.3. RRLC Method Development and Validation  
The chromatographic conditions, such as the mobile phase composition, elution gradients, and 
column temperature, were optimized during the development of the RRLC methods. Acetonitrile was 
chosen over methanol for its ability to reduce back-pressure and achieve better separation. BA-TPQ Mar. Drugs 2012, 10  1143 
 
 
(Figure 1b) was chosen as the internal standard due to its similarity to FBA-TPQ in terms of 
extractability and chromatographic behavior [11,12,22,23]. 
2.3.1. Chromatographic Separation and UV Detection of FBA-TPQ in Different Matrices 
The specificity of the RRLC assay was examined using the chromatographic conditions described 
in the Experimental section. Representative chromatograms of blank mouse plasma, control mouse 
plasma spiked with 0.5 µM FBA-TPQ, and a plasma sample obtained from a BALB/c mouse five 
minutes after intravenous administration of 5 mg/kg are shown in Figure 4a–c. Representative 
chromatograms of blank lung tissue, a control lung tissue sample spiked with 0.5 µM FBA-TPQ, and  
a lung tissue sample obtained from a BALB/c mouse five minutes after intravenous administration of  
5 mg/kg are shown in Figure 4d–f. Similar chromatograms were obtained for the other tissues examined. 
The specificity was demonstrated by the absence of any endogenous interference in the biological 
samples at the retention time of the peaks of FBA-TPQ and internal standard (BA-TPQ).  
Figure 4. Chromatograms of FBA-TPQ obtained using the optimized method. (a) A blank 
mouse plasma sample; (b) A mouse plasma sample spiked with 0.5 µM FBA-TQP;   
(c) A plasma sample collected 0.08 h after intravenous (iv) administration of (Dose = 5 mg/kg) 
FBA-TPQ; (d) A blank lung sample; (e) A lung sample spiked with FBA-TPQ at 0.5 µM; 
(f) A lung sample collected 0.08 h after iv injection of FBA-TPQ.  
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2.3.2. Linearity of the Calibration Curve, Lower Limit of Detection, and Lower Limit of Quantitation 
Calibration curves (peak area ratio of the analyte derivative to the IS derivative versus the nominal 
analyte concentration) were fitted by weighted (1/x
2) least-square linear regression. The correlation 
coefficient of the calibration curves for FBA-TPQ in plasma and various tissues were all above 0.9937. 
All of the linearity and range parameters are shown in Table 1, along with the associated validation data.  
Table 1. FBA-TPQ Standard Curve Calculation by Least Squares Regression Analysis. 
Tissue LOD  (µM)  LOQ  (µM)  Linear Fit  Correlation Coefficient (R)  Linear Range (µM) 
Plasma 0.010  0.050 Y = 0.7206x + 0.0015  0.9963  0.050–10 
Liver 0.020  0.050  Y = 0.7465x + 0.0370  0.9937  0.050–10 
Brain 0.020  0.050  Y = 0.6637x + 0.0238  0.9989  0.050–10 
Spleen 0.020  0.050 Y = 0.7810x + 0.0018  0.9964  0.050–10 
Heart 0.020  0.050  Y = 0.7242x + 0.0183  0.9965  0.050–10 
Lungs 0.020  0.050  Y = 0.6707x + 0.0016  0.9946  0.050–20 
Kidneys 0.020  0.050 Y = 0.7281x + 0.0036  0.9993  0.050–20 
The lower limits of detection (LLOD) and lower limits of quantitation (LLOQ) for FBA-TPQ using 
the optimized conditions were 0.01 and 0.05 μM, respectively in mouse plasma. The coefficient of 
variation (CV) was 5.04% and the accuracy was 118.52 ± 3.4% at the LLOQ. 
2.3.3. Precision and Accuracy 
Table 2 shows the intra- and inter-day precision and accuracy for the detection of FBA-TPQ in 
mouse plasma and tissues using the RRLC method. The accuracy was defined as the percentage of the 
concentration that was present after being calculated from peak areas compared to the known 
concentration of prepared samples. Precision was defined as the variation between replicate samples. 
The intra- and inter-day coefficients of variation for FBA-TPQ were <5.41% and <11.4%, respectively. 
The accuracy of the quantitative analysis of the compound ranged from 91.0 to 119.0% for the   
intra-day and 93.73 to 116.0% for the inter-day analyses. Both the precision and accuracy were well 
within the acceptable range as described by the FDA [24].  
Table 2. The accuracy and precision of the FBA-TPQ RRLC method in various tissue samples. 
Tissue 
Theoretical 
Concentration 
(µM) 
Intra-Day Assay (n = 5)  Inter-Day Assay (n = 4) 
Measured 
Concentration (µM)
RSD 
(%) 
Accuracy 
(%) 
Measured 
Concentration (µM) 
RSD  
(%) 
Accuracy 
(%) 
Plasma 
0.100  0.100 ± 0.005  5.41  100  0.100 ± 0.010  11.4  98.7 
2.00  2.03 ± 0.058  2.86  101  2.07 ± 0.112  5.41  100 
10.0  10.3 ± 0.026  0.251  103  9.94 ± 1.46  14.6  99.4 
Liver 
0.100  0.100 ± 0.010  12.7  99.7  0.103 ± 0.010  9.56  103 
2.00  2.01 ± 0.010  0.440  100  2.03 ± 0.010  0.550  101 
10.0  4.99 ± 0.089  0.570  102  10.2 ± 0.030  0.310  102 
Brain 
0.100  0.0510 ± 0.004  14.2  101  0.096 ± 0.013  13.1  95.7 
2.00  0.522 ± 0.038  1.19  104  2.06 ± 0.022  1.06  103 
10.0  4.80 ± 0.199  3.62  96.0  9.79 ± 0.410  4.19  97.9 Mar. Drugs 2012, 10  1145 
 
 
Table 2. Cont. 
Spleen 
0.100  0.101 ± 0.001  0.571  100  0.101 ± 0.001  0.990  101 
2.00  1.99 ± 0.023  0.330  98.5  1.97 ± 0.007  1.18  99.5 
10.0  10.3 ± 0.176  0.708  102  10.2 ± 0.073  1.71  102 
Heart 
0.100  0.100 ± 0.001  1.00  100  0.100 ± 0.001  0.580  99.7 
2.00  1.93 ± 0.025  1.27  96.4  1.96 ± 0.022  1.13  98.0 
10.0  10.4 ± 0.267  2.58  103  10.1 ± 0.070  0.700  101 
Lungs 
0.100  0.0910 ± 0.008  8.79  91.0  0.0920 ± 0.001  1.09  92.0 
5.00  4.57 ± 0.114  2.50  91.3  4.69 ± 0.106  2.28  93.7 
20.0  23.0 ± 0.008  0.0300 115  23.0 ± 0.056  0.250  114 
Kidneys 
0.100  0.119 ± 0.001  0.841  119  0.116 ± 0.007  5.97  116 
5.00  4.85 ± 0.075  1.54  97.1  4.84 ± 0.057  1.17  96.8 
20.0  21.8 ± 0.083  0.382  109  21.8 ± 0.026  0.120  109 
2.3.4. Extraction Recovery 
The extraction recoveries of the compound were determined at low (0.1 μM), medium (2.0 μM), 
and high (10 μM) concentrations (in triplicate) in plasma, and in spleen, liver, brain and heart homogenates, 
and at low (0.1 μM), medium (5.0 μM), and high (20 μM) concentrations (in triplicate) in lung and 
kidney homogenates. The recovery percentages for the compound extracted from mouse plasma and 
various tissues at the three concentrations are shown in Table 3. In general, the recovery at lower 
concentration (0.1 μM) was lower than that of higher concentrations. However, these differences 
would not affect the standard curve preparation and the results of drug analysis of the biological 
samples, due to the use of the internal standard and the same procedures used in the preparation of the 
standard curves and the actual biological samples. 
Table 3. Recovery of FBA-TPQ from various tissue homogenates. 
Tissue Concentration  (μM)  Recovery (%) ± SD (n = 5)  RSD (%) 
Plasma  0.100  83.6 ± 0.71  0.991 
5.00  95.3 ± 1.36  1.55 
10.0  90.9 ± 2.72  2.91 
Liver  0.100  77.5 ± 3.99  5.58 
5.00  87.8 ± 4.48  5.96 
10.0  94.8 ± 2.58  2.99 
Brain  0.10  72.4 ± 3.21  4.39 
5.00  82.4 ± 0.96  1.17 
10.0  89.7 ± 0.58  0.66 
Spleen  0.100  75.3 ± 2.34  3.16 
5.00  91.9 ± 2.06  2.41 
10.0  95.1 ± 2.00  2.28 
Heart  0.100  83.2 ± 0.71  1.75 
5.00  93.2 ± 1.36  2.20 
10.0  96.4 ± 2.72  0.210 
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Table 3. Cont. 
Lungs  0.100  75.7 ± 1.32  5.62 
5.00  86.3 ± 1.72  0.320 
20.0  85.7 ± 0.17  0.84 
Kidneys  0.100  75. 9 ± 2.75  3.74 
5.00  88.8 ± 1.24  1.58 
20.0  95.5 ± 1.54  1.86 
2.3.5. Stability  
The stability experiments showed that FBA-TPQ was stable for 24 h after preparation at 22 °C, for 
2 h at 22 °C following three freeze/thaw cycles (−20 to 22 °C) on consecutive days, and for 3 months 
at −80 °C, as the RE values were within ±15% for both the low and high concentrations. Taken 
together, the stability data indicated that FBA-TPQ in plasma and tissue samples could be stored and 
prepared under routine laboratory conditions. 
2.4. Protein Binding  
To determine the extent to which FBA-TPQ is bound by plasma proteins, pooled plasma samples 
were examined for their capacity to bind the compound at concentrations of 0.5 μM and 5 μM.  
FBA-TPQ was considerably bound to proteins in mouse plasma, with 72.32% ± 2.53%; and 77.78% ± 1.17% 
of the compound being bound to plasma proteins at concentrations of 0.5 μM and 5.0 μM, respectively. 
Extensive binding of a candidate compound to plasma proteins can impair its biodistribution and may 
therefore impact its therapeutic efficacy. However, compounds that are highly bound to proteins 
display longer half-lives, durations of action, and higher volumes of distribution. In the present study, 
FBA-TPQ exhibited considerable protein binding, which may have limited the in vitro degradation of 
the compound, as described below.  
2.5. Metabolism by Mouse S9 Enzymes 
As a preliminary study of the metabolism of FBA-TPQ, the compound was incubated with S9 
fractions containing Phase I and Phase II metabolic enzymes and their co-factors for 15, 30, 45, or  
60 min. These studies indicated that FBA-TPQ undergoes significant metabolism in the presence of 
both Phase I and Phase II enzymatic components, with approximately 14.3% of the compound being 
metabolized by Phase I and 1.8% of the compound being metabolized by Phase II components during 
the 60 min incubation. No specific peaks that seemed to correspond to unique metabolites were identified 
using the current RRLC method. 
2.6. Pharmacokinetics of FBA-TPQ in Mice  
To assess the disposition of FBA-TPQ in vivo, pharmacokinetic studies in BALB/c were conducted. 
The results of the mean plasma concentration-time curves of FBA-TPQ, and tissue concentration-time 
curves of FBA-TPQ, after intravenous or intraperitoneal injection in BALB/c mice are presented in 
Figure 5. Two-compartmental model (WinNonlin 6.0 Model 7, Pharsight Corporation: Mountain View, Mar. Drugs 2012, 10  1147 
 
 
CA, USA, 2009) was used to analyze the data obtained following intravenous (iv) and intraperitoneal (ip) 
administration of the compound. The pharmacokinetic parameters are presented in Table 4. 
After a single bolus intravenous dose of FBA-TPQ (5 mg/kg), there were relatively high concentrations 
of the compound in the plasma for the first 30 minutes, with a rapid decline thereafter, as indicated by 
its half-life of 0.248 h, and clearance rate of 8.46 (L/hr/kg) in BALB/c mice (Table 4). The iminoquinone 
was no longer detectable in mouse plasma 4 h after the injection. The highest overall concentrations in 
the tissues examined were in the order kidneys > lungs > heart > spleen > plasma ≈ liver > brain. 
Figure 5. (a) Mean plasma concentration-time curves of FBA-TPQ after intravenous and 
intraperitoneal injection in BALB/c mice (mean ± SD); (b) Mean tissue concentration-time 
curves of FBA-TPQ after intravenous and intraperitoneal injection in BALB/c mice   
(mean ± SD). 
 
Table 4. Pharmacokinetic parameters for FBA-TPQ following intravenous or 
intraperitoneal injection in BALB/c mice. 
Tissue Route  Dose  (mg/kg) T1/2 (h) AUC (h·µg/mL)  Cl (L/h/kg)  Vss (mL/g)
Plasma 
iv 5  0.248  0.583  8.46  18.7 
ip 10  0.219  0.338  19.8 21.8 
Liver 
iv 5  0.510  0.949  4.70  3.34 
ip 10  0.127 1.85  3.85 6,72 
Brain 
iv 5  0.252  0.138  34.5  18.7 
ip 10 1.83  0.0623  2.13 4.10 Mar. Drugs 2012, 10  1148 
 
 
Table 4. Cont. 
Spleen 
iv 5  0.081  2.33  1.98  1.27 
ip 10 1.73 6.50  0.932  0.78 
Heart 
iv 5  0.502  2.00  2.47  1.77 
ip 10  0.541 2.36  3.85 2.19 
Lungs 
iv 5  0.501  4.02  1.237  7.79 
ip 10  0.363 5.71  1.88  10.32 
Kidneys 
iv 5  0.251  11.5  0.436  0.491 
ip 10 1.58 14.7  0.823  0.801 
T1/2: half-life of the compound; AUC: area under the concentration-time curve; Cl: clearance; Vss: volume in 
steady state.  
Following intraperitoneal administration, the concentration of the compound in plasma decreased 
rapidly from 542.5 ng/mL at 5 min to 40.25 ng/mL at 2 h, to undetectable levels 4 h after 
administration. The highest overall tissue concentrations after intraperitoneal injection were in the 
order: kidneys > spleen > lungs > liver > heart > brain. The intraperitoneal bioavailability of FBA-TPQ 
in BALB/c mice was estimated to be 28.91%, based on the AUC values. 
The pharmacokinetic profiles for the tissues obtained in our study suggest that there is high drug 
accumulation in the lungs, kidneys, and spleen of the mice, and that it reaches low concentrations in 
the brain. Furthermore, pharmacokinetic modeling confirmed that these tissues exhibited the highest 
drug exposure (AUC), longest half-life, and lowest clearance values, indicating that these organs may 
be potential sites of FBA-TPQ toxicity. 
Our study also investigated the pharmacokinetic profile of FBA-TPQ following both intravenous  
(5 mg/kg) and intraperitoneal (10 mg/kg) administration. Based on the AUC values, the bioavailability 
of FBA-TPQ following intraperitoneal injection was relatively low, presumably because FBA-TPQ 
underwent extensive metabolism after ip injection and/or distributed in tissues quickly. Ultimately, it 
would be optimal if the compound could be administered orally, because patients greatly prefer oral 
agents. Studies are currently underway to develop a method for oral delivery of the compound. 
3. Experimental Section  
3.1. Test Compound, Chemicals and Reagents  
FBA-TPQ and BA-TPQ (Figure 1a,b) were kindly provided by Dr. Sadanandan Velu (University of 
Alabama at Birmingham). Acetonitrile and methanol were purchased from Fisher Scientific (Atlanta, 
GA, USA). All other chemicals were purchased from Sigma Chemical Company (St. Louis, MO, USA). 
Heparinized samples of non-Swiss albino mouse plasma were obtained from Lampire Biological 
Laboratories (Pipersville, PA, USA). Hepatic S9 fractions (20 mg/mL) from male ICR/CD-1 mice 
were purchased from Celsis In Vitro Technologies (Chicago, IL, USA). All chemicals and solvents 
used for sample preparation and the rapid resolution liquid chromatography analysis were of analytical 
grade. Cell culture supplies and media, phosphate-buffered saline (PBS), fetal bovine serum (FBS), 
sodium pyruvate, non-essential amino acids, and penicillin-streptomycin were obtained from 
Invitrogen (Carlsbad, CA, USA). 
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3.2. Cell Culture 
Human pancreatic cancer cells were obtained from the American Type Culture Collection 
(Rockville, MD). All cell culture media contained 10% FBS and 1% penicillin/streptomycin. HPAC 
cells were grown in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 medium 
containing 1.2 g/L sodium bicarbonate, 2.5 mM L-glutamine, 15 mM HEPES and 0.5 mM sodium 
pyruvate supplemented with 2 µg/mL insulin, 5 µg/mL transferrin, 40 ng/mL hydrocortisone,   
10 ng/mL epidermal growth factor and 5% fetal bovine serum. Panc-1 cells were cultured with   
RPMI 1640 containing 1 mM HEPES buffer, 25 µg/mL gentamicin, 1.5 g/L sodium bicarbonate, and  
0.25 µg/mL amphotericin B. Mia PaCa-2 and IMR-90 cells were grown in DMEM media.  
3.3. MTT Cell Survival Assay 
The effect of the test compound on human pancreatic cancer cell viability, expressed as the 
percentage of cell survival, was determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) assay. The MTT assay is colorimetric assay for measuring the activity of 
enzymes that reduce MTT to formazan dyes, giving a purple color. Cells were grown in 96-well plates 
at 4–5 × 10
3 cells per well and exposed to different concentrations of the test compound (0, 0.1, 0.25, 
0.5, 0.75, 1, 5 and 10 µM). After incubation for different times, 10 µL of the MTT solution (5 mg/mL; 
Sigma; St. Louis, MO, USA) were added into each well. The plates were incubated for 2–4 h at 37 °C. 
The supernatant was then removed and the formazan crystals were dissolved with 100 µL of DMSO. 
The absorbance at 570 nm was recorded using an OPTImax microplate reader (Molecular Devices; 
Sunnyvale, CA, USA). The cell survival percentages were calculated by dividing the mean OD of 
compound-containing wells by that of DMSO-containing control wells. Three separate experiments 
were accomplished to determine the IC50 values. 
3.4. Detection of Apoptosis 
Following a similar protocol as above, cells in early and late stages of apoptosis were detected using 
an Annexin V-FITC apoptosis detection kit from BioVision (Mountain View, CA, USA), according to 
the manufacturer’s protocol. For apoptosis experiments, 2–3 × 10
5 cells were exposed to the test 
compound (0, 0.1, 0.5 and 1.0 µM) and incubated for 48 h prior to analysis. Cells were collected and 
washed with serum-free media. Cells were then re-suspended in 500 µL of Annexin V binding buffer 
followed by addition of 5 µL of Annexin V-FITC and 5 µL of propidium iodide (PI). The samples 
were incubated in the dark for 5 min at room temperature and analyzed with a Becton Dickinson 
FACSCalibur instrument (Ex = 488 nm; Em = 530 nm). Cells that were positive for Annexin V-FITC 
alone (early apoptosis) and Annexin V-FITC and PI (late apoptosis) were counted. The apoptotic index 
was calculated against the untreated control cells. 
3.5. Cell Cycle Measurements  
To determine the effect of FBA-TPQ on the cell cycle, cells (2–3 × 10
5) were exposed to the test 
compounds (0, 0.1, 0.5 or 1 µM) and incubated for 24 h prior to analysis. Cells were trypsinized, 
washed with PBS, and fixed in 1.5 mL of 95% ethanol and 0.5 mL of 0.9% saline solution at 4 °C Mar. Drugs 2012, 10  1150 
 
 
overnight, followed by incubation with RNAse and staining with propidium iodide (Sigma). The DNA 
content was determined by flow cytometry. The cell cycle distribution was evaluated by comparing 
with that of the control cells.  
3.6. Instruments and Conditions 
An Agilent 1200 Series Rapid Resolution Liquid Chromatography system (Agilent Technologies, 
Waldbronn, Germany) consisted of an on-line degaser, a binary pump, a high performance SL 
autosampler, a thermostated column compartment, and a photodiode array UV-vis detector. Determination 
of FBA-TPQ was achieved using a Zorbax XDB-C18 (1.8 μm, 50 × 4.6 mm) analytical column with a 
LiChroCART 100 RP-18 guard column. The column eluate was monitored by a diode array detector at 
354 nm. The temperature was maintained at 35 °C. The system was set to use a linear gradient at a 
flow rate of 0.9 mL/min, increasing the acetonitrile-water ratio from 10:90 at 0 min to 38:62 at   
3.5 min, keeping this ratio until 5 min, and then increasing to 85:15 in 0.1 min, maintaining this ratio 
for 1 min, and then returning to 10: 90 in 0.4 min, for a total running time of 8 min.  
3.7. Preparation of Calibration Standards and Quality Control Samples 
A 1 mM stock solution of FBA-TPQ was prepared in methanol and stored at −80 °C. A series of 
standard working solutions with FBA-TPQ concentrations of 0.1, 0.25, 0.5, 1.0, 5.0, 10.0, 50.0 and 
100.0 μM were obtained by further dilution of the stock solution with methanol. The standard serum 
samples for calibration were prepared at concentrations of 0.1, 0.25, 0.5, 1.0, 5.0, and 10.0 μM in 
control (drug-free) pooled mouse plasma.  
Calibration curves were prepared by spiking 20 μL of the appropriate standard solution and 20 μL 
BA-TPQ (IS) into 160 μL of blank mouse plasma. The 40 µM BA-TPQ solution was prepared by 
diluting a stock solution of 100 µM BA-TPQ with methanol. Quality control samples of low, medium 
and high concentrations were prepared to assess the accuracy and precision of the bioanalytical 
method. For the calibration of the tissue samples, a plasma sample was supplemented with tissue 
homogenates in PBS.  
3.8. Sample Preparation 
Acetonitrile (600 μL) and BA-TPQ (IS, 20 μL) were added to 200 μL of plasma to precipitate 
proteins. The mixture was vigorously vortexed for 1 min and centrifuged at 14,000 × g for 10 min. 
Then, the supernatant was transferred to a glass tube and evaporated to dryness at 40 °C under a stream 
of nitrogen in a TurboVap
® LV Concentration Workstation (Caliper Lifesciences, Hopkinton, MA, 
USA). The resulting supernatant was transferred to a new glass tube and evaporated to dryness. 
Finally, samples were reconstituted in 200 μL mobile phase, and 10 μL was injected into the RRLC 
system for analysis. 
3.9. Method Validation 
To confirm its accuracy, selectivity, reproducibility, and specificity, the method was validated as 
follows: Evaluation of the method selectivity was performed by analyzing the blank plasma from six Mar. Drugs 2012, 10  1151 
 
 
different preparations to test for interference at the retention times of the analyte. The linearity of the 
method was determined by plotting the peak area ratios of the analyte to the internal standard (IS) 
against the concentrations of FBA-TPQ in mouse plasma and various tissues. This was done in 
duplicate on three consecutive validation days. The precision and accuracy of the method were 
assessed by the determination of QC samples at three concentration levels, in six replicates, on three 
validation days. For the intra- and inter-day precision, we required that there was less than 15% 
variation, and also required the accuracy to be within ±15%, which is within the limits proposed in the 
US FDA guidelines [24]. Limit of detection (LOD) was the lowest concentration of an analyte that the 
bioanalytical procedure can reliably differentiate from background noise. The LLOQ, defined as the 
lowest concentration on the calibration curve at which both precision and accuracy were less than or 
equal to 20%, was evaluated by analyzing samples prepared in six replicates on three consecutive 
validation days [24]. The recovery of FBA-TPQ was determined by comparing the mean peak   
areas of the pretreated QC samples at three concentration levels (six samples each) to those of   
spike-after-extraction samples. 
3.10. Stability in Plasma 
The stability of FBA-TPQ was evaluated at two concentrations (0.5 and 5.0 µM). The compound 
was incubated under the following conditions: 37 °C for 0, 1, 2, 4, and 8 h; 4 °C for 0, 1, 4, 8, and  
24 h; and −80 °C for 0, 1, 2, 4, and 12 weeks. At the designated time points, the samples were 
extracted and analyzed using the established RRLC analytical method. The stability of FBA-TPQ was 
assessed by comparing the initial concentration (time 0) with the final concentration following 
incubation of the compound at the noted temperatures, and expressing this difference as a percentage 
of the initial concentration. 
3.11. Binding to Plasma 
The extent of binding to mouse plasma proteins by FBA-TPQ was determined using a   
micro-ultrafiltration system as previously described [25]. FBA-TPQ was dissolved in methanol and 
added to pooled mouse plasma to yield final concentrations of 0.5 µM and 5.0 µM. Control solutions 
were prepared in methanol to account for non-specific binding of FBA-TPQ to the filter membranes. 
Duplicate preparations of each concentration were incubated at 37 °C for 1 h, before being placed into 
the sample reservoirs of Amicon Centrifree
® ultrafiltration tubes (30 kDa exclusion; Millipore). 
3.12. S9 Metabolism 
A preliminary study of the metabolism of FBA-TPQ was done using murine hepatic S9 fractions 
containing Phase I and II metabolic enzymes. The reaction mixture contained 10 μM FBA-TPQ   
(in methanol), 1 mg/mL S9 and 100 mM Tris buffer (pH 7.4) (experimental controls did not contain 
the hepatic S9 fractions.) Metabolic reactions were initiated by adding NADPH-regenerating systems 
to the reaction mixtures, and samples were incubated in a water bath at 37 °C. Duplicate aliquots of the 
mixtures were taken at 0, 15, 30, 45, and 60 min, and the samples were processed and analyzed.  
The percent of FBA-TPQ that was metabolized by Phase I and Phase II enzymes was calculated   Mar. Drugs 2012, 10  1152 
 
 
by comparing the initial concentration of the iminoquinone to the measured concentration   
following incubation. 
3.13. Animals 
3.13.1. Mouse Xenograft Model of Human Pancreatic Cancer  
The animal use and care protocol was approved by the Institutional Animal Use and Care 
Committee of Texas Tech University Health Sciences Center.  Female athymic pathogen-free nude 
mice (nu/nu, 4–6 weeks) were purchased from the Charles River Laboratories International. Inc. 
(Wilmington, MA, USA). To establish Panc-1 human pancreatic cancer xenograft tumors, cultured 
Panc-1 cells were harvested from monolayer cultures, washed twice with serum-free medium,   
re-suspended and injected sc (5 × 10
6 cells, total volume 0.2 mL) into the left inguinal area of the mice. 
All animals were monitored for activity, physical condition, body weight, and tumor growth. Tumor 
size was determined every other day by caliper measurement of two perpendicular diameters of the 
implant. Tumor mass (in g) was calculated by the formula, 1/2a × b
2 where “a” is the long diameter 
and “b” is the short diameter (in cm). 
The animals bearing human cancer xenografts were randomly divided into various treatment groups 
and a control group (7–10 mice/group). The untreated control group received the vehicle only. For the 
Panc-1 xenograft model, FBA-TPQ was dissolved in PEG400: ethanol: saline (57.1: 14.3: 28.6, v/v/v), 
and was administered by intraperitoneal (ip) injection at doses of 5 and 10 mg/kg/d, 5 d/wk for 3 weeks.  
3.13.2. Pharmacokinetic Studies in Mice 
Female BALB/c (18–20 g) mice were purchased from Harlan Laboratories (Indianapolis, IN). All 
animals were fed with commercial diet and water ad libitum and were on an alternating 12 h light/dark 
cycle. The mice were randomly divided into groups of three, and were dosed  either  
intravenously (5 mg/kg) or intraperitoneally (10 mg/kg) with FBA-TPQ in PEG 400: ethanol: saline 
(57.1%:14.3%:28.6%). Before dosing, and at 5, 15, 30, and 60 min, and 2, 4, 8, and 24 h after dosing, 
groups of animals (three/time point) were anesthetized, and blood was collected from the retro-orbital 
sinus into heparinized tubes. Plasma was obtained by centrifuging the blood samples at 14,000 rpm for 
15 min. FBA-TPQ was then extracted from plasma and stored at −80 °C until analysis. The brain, heart, 
kidneys, liver, lungs, and spleen were also collected at the same time points during necropsy, blotted 
on Whatman No. 1 filter paper, trimmed of extraneous fat and connective tissue, weighed, and 
homogenized in phosphate-buffered saline. The resulting homogenates were stored at −80 °C until 
further processing and analysis.  
The average FBA-TPQ concentrations in plasma and tissues at each of the time points following 
intravenous and intraperitoneal administrations were used for pharmacokinetic analyses using a one- or 
two-compartmental model, respectively. The following pharmacokinetic parameters were estimated 
using Phoenix WinNonlin 6.0 (Mountain View, CA, USA): area under the concentration-time curve 
(AUC, h·μg/mL), half-life (T½, h), maximum concentration (Cmax,  μg/mL), time of the maximum 
concentration (Tmax, h), and clearance (CL, mL/h/kg), as applicable. Bioavailability (X) was calculated 
as X = [AUCip × doseiv]/[AUCiv × doseip]. Mar. Drugs 2012, 10  1153 
 
 
3.14. Data and Statistical Analysis 
Experimental data are expressed as means and standard deviations, and the significance of 
differences was analyzed by ANOVA or Student’s t-test, as appropriate.  
4. Conclusions  
The present study was the first to systematically investigate the novel synthetic makaluvamine 
analog FBA-TPQ’s in vitro and in vivo anti-tumor effects in pancreatic cancer cells. We observed that 
FBA-TPQ significantly decreased pancreatic cancer cell growth, induced cell apoptosis and led to cell 
cycle arrest. In a dose-dependent manner, FBA-TPQ decreased the growth of Panc-1 xenograft tumors 
with minimal host toxicity. To facilitate preclinical and clinical development of the compound, a 
RRLC-UV method was developed and validated for the quantification of FBA-TPQ. The method 
offered the advantages of high selectivity and simple sample preparation. It was successfully applied 
for the evaluation of the pharmacokinetics of FBA-TPQ in mice, making this the first report of the 
pharmacokinetics of FBA-TPQ. In in vitro assays, FBA-TPQ was stable in plasma, bound to protein 
extensively, and metabolized by S9 enzymes. It had a short plasma half-life and a wide tissue 
distribution in BALB/c mice. The results provide a basis for further preclinical and clinical studies of 
the compound as a candidate anti-cancer agent.  
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